Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

For 2016, it's been all about TAF -

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pearsby09 Member Profile
 
Followed By 26
Posts 4,709
Boards Moderated 0
Alias Born 04/29/16
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:28:29 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 5:08:57 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 2:08:05 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 10:30:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/15/2019 8:12:12 AM
GlaxoSmithKline: Phase 3 Study of Zejula Met Trial Objectives Dow Jones News - 7/15/2019 2:43:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:13:34 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/12/2019 1:04:43 PM
EU Approves With Conditions GlaxoSmithKline's Acquisition of Pfizer's Consumer Health Business Dow Jones News - 7/11/2019 5:02:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 12:00:33 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2019 6:17:08 AM
GlaxoSmithKline, Pfizer's HIV Treatment Meets Primary Endpoint in Trial Dow Jones News - 7/10/2019 2:54:00 AM
Fulcrum Therapeutics Sets IPO at 4.5 Million Shares; Sees Pricing at $16-$18 Apiece Dow Jones News - 7/8/2019 7:13:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/3/2019 7:59:46 AM
South Africa Gives Conditional Go-Ahead to GSK-Pfizer JV -Reuters Dow Jones News - 7/2/2019 2:10:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2019 10:46:28 AM
Liquidia Technologies Gets Right to Develop More Products in Revised GlaxoSmithKline Agreement Dow Jones News - 6/26/2019 7:28:00 PM
GSK Offers Concessions on Pfizer JV to Quell EU Antitrust Fears Dow Jones News - 6/20/2019 6:53:00 AM
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
pearsby09   Wednesday, 03/01/17 03:58:24 PM
Re: None
Post # of 137 
For 2016, it's been all about TAF - sweet, sweet tenofovir alafenamide fumarate. What's so special about TAF, you ask? TAF (you may know it as Vemlidy) is replacing TDF (Viread) in a variety of HIV treatments because it's safer and less costly to produce. How much less? Here's a quote from the Q3'16 conference call:

John F. Milligan

We're particularly excited about the role that TAF will play. With a small daily dose and improved side effect profile, it is ideal for resource-constrained areas of the world and requires only one-tenth of the manufacturing capacity to supply the same number of patients.
TAF's manufacturing efficiency bodes well for the future profit margins in the HIV business. Now how about safety? TAF is both safer for renal health and bone density. This abstract from CROI illustrates the point clearly. 0 out of 866 patients developed clinically significant renal issues on TAF, whereas 12 out of 867 patients developed renal issues on TDF. This is statistically significant, and the efficacy results are similar. All you need to know is TAF is a safer version of TDF, and that safety is paramount in HIV treatment.

In the HCV market, side effects are important. However, they are even more crucial in HIV because the disease is chronic. In other words, treatment durations are decades rather than a few weeks. Drug-drug interactions, side effects, PK and PD data, and various other factors play a huge role in these lifetime treatment fields. TAF solved long-term concerns related to renal and bone damage seen with TDF treatments, leading to fast uptake.

When Gilead released TAF, it was quickly adopted as a preferred treatment in the US Department of Health & Human Services (DHHS) and International Antiviral Society (IAS) guidelines. It has also been adopted in the guidelines of a variety of other countries such as Germany, the UK, Spain, and Italy. In addition, guidelines are starting to label TDF-backed regimens as alternative treatments. A quote from the Wells Fargo broker conference back in September 2016 illustrates the importance of this:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist